These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 4907149

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Propranolol and hypoglycemic sulfonamides. Study on insulin secretion and blood sugar].
    Loubathières A, Mariani MM, Ribes G, Chapal J.
    C R Seances Soc Biol Fil; 1971; 165(6):1393-7. PubMed ID: 4262051
    [No Abstract] [Full Text] [Related]

  • 4. [Physiological and pharmacological aspects of the central role of the pancreas in the mode of action of hypoglycemic sulfonamides].
    Loubatières A.
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():216-55. PubMed ID: 4906020
    [No Abstract] [Full Text] [Related]

  • 5. [Effect of HB 419 and tolbutamide on isolated islands of Langerhans in rats].
    Löffler G, Trautschold I, Schweitzer T, Lohmann E.
    Arzneimittelforschung; 1969 Aug; 19(8):Suppl:1469-72. PubMed ID: 4899090
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tolbutamide and diazoxide influence insulin secretion by changing the concentration but not the action of cytoplasmic Ca2+ in beta-cells.
    Mariot P, Gilon P, Nenquin M, Henquin JC.
    Diabetes; 1998 Mar; 47(3):365-73. PubMed ID: 9519741
    [Abstract] [Full Text] [Related]

  • 13. The morphological substrate of the inhibition of insulin secretion by diazoxide.
    Creutzfeldt W, Creutzfeldt C, Frerichs H, Perings E, Sicklinger K.
    Horm Metab Res; 1969 Mar; 1(2):53-64. PubMed ID: 4334867
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Recent pharmacologic aspects of sulfamides modifying insulin secretion (hypoglycemic and hyperglycemic sulfamides)].
    Loubatiéres A, Mariani MM.
    Actual Physiol Pathol (Paris); 1973 Mar; 4():237-66. PubMed ID: 4219256
    [No Abstract] [Full Text] [Related]

  • 19. [Comparison of the beta-cytotrophic effect of a new sulfonylurea derivative, glibornuride, and tolbutamide].
    Bottermann P, Souvatzoglou A, Schwarz K, Rettig M.
    Klin Wochenschr; 1971 Jul 01; 49(13):769-70. PubMed ID: 4935073
    [No Abstract] [Full Text] [Related]

  • 20. Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets.
    Panten U, Burgfeld J, Goerke F, Rennicke M, Schwanstecher M, Wallasch A, Zünkler BJ, Lenzen S.
    Biochem Pharmacol; 1989 Apr 15; 38(8):1217-29. PubMed ID: 2650685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.